Full-Time

Digital Lead for Medical, Regulatory Affairs & Pharmacovigilance Platforms

Regulatory Affairs & Pharmacovigilance Platforms

Deadline 6/26/26
Opella

Opella

1,001-5,000 employees

No salary listed

Paris, France + 2 more

More locations: Hyderabad, Telangana, India | Sant Cugat del Vallès, Barcelona, Spain

In Person

Category
Legal & Compliance (2)
,
Required Skills
Veeva
FDA Regulations
Data Analysis
Requirements
  • Bachelor’s degree in a relevant field; Master’s degree preferred
  • Proven extensive experience in digital leadership roles within the Lifesciences or consumer healthcare industry
  • Proven experience in overseeing and implementing digital systems like Medical Affairs event platforms, RIMS and publishing platforms and ARIS or similar PV Platforms to optimize adverse event monitoring, case processing, and regulatory compliance
  • Strong understanding of Medical affairs, Regulatory Affairs and Pharmacovigilance processes
  • Exceptional leadership and team management skills
  • Excellent communication and stakeholder engagement abilities
  • Demonstrated ability in evaluating, negotiating, and managing contracts and Statements of Work with Medical, Regulatory Affairs and Pharmacovigilance technology vendors and implementation/support providers
  • Comprehensive knowledge of Quality Assurance and regulatory compliance, including 21 CFR Part 11 and FDA regulations
  • Strong problem-solving capabilities and a track record of successful project delivery
  • Languages: Advanced English required, Spanish or French preferred
Responsibilities
  • Strategic Technology Liaison: Act as the pivotal link between the Global Science- Medical RA & PV functions, and technology providers, overseeing the delivery of digital solutions for Medical, RA & PV information. Establish and maintain strategic vendor relationships and governance structures
  • Digital Strategy: Develop and execute a comprehensive digital strategy for Medical, RA and PV platforms, aligning with organizational goals and regulatory requirements
  • Technical Solutions Leadership: Lead discussions on technical feasibility, prototype development, and the design of efficient, adaptable, and scalable technology solutions, all in adherence to company policies, regulatory standards, and integration goals
  • Team Leadership: Build, mentor, and lead a high-performing team of digital experts (both internal & external) focused on Medical, RA and PV domains, fostering innovation and excellence
  • Technology Roadmap Execution: Manage the execution of the approved technology roadmap, ensuring the delivery of development and validation artifacts to meet high-quality standards, compliance, and audit readiness
  • Platform Enhancement: Drive the enhancement and optimization of digital platforms used in Medical Affairs, Regulatory Affairs and pharmacovigilance, ensuring efficiency and compliance
  • Stakeholder Collaboration: Collaborate closely with Medical Affairs, Regulatory Affairs, PV, Digital, and other relevant departments to align digital initiatives and ensure seamless integration of digital solutions
  • Application Support Management: Supervise both daily and scheduled support for Medical RA & PV platforms collaborating with managed support teams both internal and external eto resolve issues with the highest level of quality and stakeholder satisfaction
  • Vendor Management: Oversee relationships with technology vendors and service providers, ensuring the delivery of high-quality solutions and services
  • Data Insights: Leverage data analytics and insights to inform decision-making, optimize processes, and drive continuous improvement in Medical, RA and PV operation
  • Regulatory Compliance: Ensure that relevant digital platforms and processes comply with all relevant regulatory requirements, maintaining the highest standards of quality and safety
  • Budget Oversight: Manage the budget for digital initiatives within Medical, RA and PV, optimizing resources for maximum strategic impact
  • Platform Compliance: Collaborate with relevant stakeholders to ensure that solutions, such as Global Safety Database- ARIS G- LifeSphere MultiVigilance (LSMV), Veeva RIMS and Medical Affairs Global HCP Events platform, are developed in line with the requirements of 21 CFR Part 11 and systems validation standards
Desired Qualifications
  • Soft skills: Strong communication skills
  • Soft skills: negotiation and interpersonal skills
  • Soft skills: Demonstrated conflict resolution & problem-solving skills in a global environment
  • Soft skills: Strong appetite to learn and discover, entrepreneur mindset
  • Soft skills: Adaptable and open to change
  • Soft skills: Team player, service-oriented
  • Soft skills: Analytical and synthetic, able to formalize solutions, good writing skills
  • Soft skills: Strong oral and written communication skills
  • Soft skills: With leadership attitude, autonomy and results driven
  • Soft skills: Role model our 4 values: teamwork, integrity, respect, courage

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Neuilly-sur-Seine, France

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • ARENA grants $1.94M for Queensland site electrification, cutting Scope 1 emissions.
  • Navan partnership targets 20% travel cost savings and 95% adoption rate.
  • Opella achieved €5B revenues in 2024 as self-care market leader.

What critics are saying

  • KKR's €2.6B Karo Healthcare buyout erodes Opella's European OTC share.
  • French backlash forces Doliprane divestiture, disrupting core domestic sales.
  • CD&R cost-cutting triggers layoffs of 11,000 employees within 12 months.

What makes Opella unique

  • Opella holds third-largest global OTC and VMS portfolio with 100 brands.
  • Opella operates 13 manufacturing sites and 4 innovation centers worldwide.
  • Opella became independent via CD&R's €10B buyout from Sanofi in April 2025.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Opella who can refer or advise you

Benefits

Hybrid Work Options

Company News

Carroll County News
Apr 15th, 2026
Navan selected by Opella to streamline global travel and expense.

Navan selected by Opella to streamline global travel and expense. * 1 hr ago Navan (NASDAQ: NAVN), the global AI-powered business travel and expense management platform, today announced it has been selected by Opella to manage its global travel and expense programme. Self-care company aims to simplify employee T&E experience and targets cost savings with AI-powered platform "Navan provides our teams with an easy-to-use tool that removes the complexity from business travel and expense, improving our employee experience and giving us the real-time visibility required to effectively manage costs," said Vincent Cotard, VP Global Head Real Estate and Workplace Experience at Opella. "Our employees will now have the easiest way to book travel and manage their expenses as we look to automate processes across the business." Following Opella's carve-out from Sanofi, the self-care company sought an AI-powered partner to provide employees with an easy-to-use travel platform and to optimize spending. Initial conversations began about Navan's travel product and Opella extended the partnership to also include Navan's expense product, giving them end-to-end control and visibility of their entire travel and expense outlay. Anticipated benefits from the partnership with Navan include: * Cost savings: Targeting savings of up to 20% on annual travel spend through access to competitive pricing and reduced fees. * High adoption: Aiming for 95% platform adoption and a 96% traveller satisfaction score. * Operational efficiency: Saving an estimated 15 minutes per booking through AI-assisted capabilities and improved self-serve access across both web and mobile applications. "We're thrilled to partner with Opella to modernise their global travel and expense programme," said Zahir Abdelouhab, SVP, EMEA, Navan. "By addressing issues with their existing inventory, we are confident that Opella will achieve the adoption rates and savings necessary to meet their goals." Opella joins a growing list of enterprise organizations that have recently switched to Navan, including industry leaders from across France, including Alcatel-Lucent, Lafarge, and Expleo. About Opella Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Its mission is to bring health into people's hands by making self-care as simple as it should be. For half a billion consumers worldwide - and counting. At the core of this mission is its 100 loved brands, its 11,000-strong global team, its 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world's most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, Mycarrollcountynews is active players in the journey towards healthier people and planet. About Navan Navan (NASDAQ: NAVN) is the global AI-powered business travel and expense platform that makes travel easy for frequent travelers. From finding flights and hotels, to automating expense reconciliation, with 24/7 support along the way, Navan delivers an intuitive experience travelers love and finance teams rely on. See how Navan customers benefit and learn more at navan.com. Forward Looking Statements All statements in this press release other than statements of historical fact could be deemed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "project," "will," or similar expressions. Such statements are subject to risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks and other factors include the risks described under the caption "Risk Factors" in Navan's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on April 2, 2026, as they may be updated by Navan's subsequent filings with the SEC. Except as required by law, Navan undertakes no obligation, and does not intend, to update these forward-looking statements. Media gallery

The Australian Pipeliner
Mar 23rd, 2026
$13 million boost for industrial decarbonisation.

$13 million boost for industrial decarbonisation. Image: zhengzaishanchu/stock.adobe.com The Australian Renewable Energy Agency (ARENA) has announced a $13 million funding package to support five projects aimed at cutting emissions across Australian industry. The investment, delivered through ARENA's National Industrial Transformation program, will back technologies designed to reduce emissions, lower long-term energy costs and strengthen low-carbon supply chains. ARENA CEO Darren Miller said decarbonising industry is critical to achieving Australia's net zero targets and requires early-stage support to unlock wider private investment. "Australia cannot reach net zero without transforming how we produce the materials, energy and goods that underpin our economy," he said. "These projects show that industrial decarbonisation is not a future aspiration but is happening now, with practical solutions that cut emissions, strengthen competitiveness and build the foundations for new low-carbon industries." Projects include: * 4 Pines Brewing Co will receive up to $1.77 million in ARENA funding to support the electrification of its Brookvale brewhouse, enabling a transition away from natural gas and positioning the site among the most advanced low-carbon breweries in Australia. * Alsco will receive up to $1.04 million to deliver its South Coast Flagship Site for Innovation and Low Carbon Demonstration, an industry-leading showcase of clean technology for automated laundry sorting and washing that reduces energy, time and resource use. * Opella Healthcare will receive up to $1.94 million to eliminate natural gas use at its Queensland manufacturing site, cutting Scope 1 emissions while maintaining essential production conditions, including temperature, humidity and water flow. * Capral will receive up to $3.45 million to replace a 40-year-old gas-fired log furnace with a fully electric furnace system at its Bremer Park aluminium extrusion facility in Queensland. The new electrically heated convection oven is expected to improve efficiency from 20% to 90% and reduce company-wide emissions. * BioCarbon will receive up to $4.80 million to construct a commercial-scale facility producing biochar pellets to replace fossil coke in electric arc furnace steelmaking. Once operational, the facility will process approximately 20,000 tonnes of waste woodchips each year to produce around 8,000 tonnes of biochar pellets and 8,000 tonnes of wood vinegar as a co-product. ARENA said the projects highlight the growing momentum of industrial decarbonisation in Australia, with initiatives already underway to electrify processes, improve efficiency and adopt low-emissions technologies across key industries

Wamda
Sep 30th, 2025
Turbostart leads $2 million round in Climaty AI

* India-founded and UAE-based climatetech Climaty AI has raised $2 million in early-stage funding led by Turbostart, with participation from AI experts and angel investors.

PR Newswire
Jun 16th, 2025
Cortizone-10® Partners With Dylan Efron And The National Park Foundation To Help Outdoor Enthusiasts Stay Itch-Free This Summer

The brand's new Itch Relief Cooling Spray helps tackle "itchsanity" one irritation at a time.MORRISTOWN, N.J., June 16, 2025 /PRNewswire/ -- Whether it's a weekend hike, a summer camping trip, or just time spent in the backyard, skin irritations can take the fun out of outdoor activities. That's why Cortizone-10®, the #1 Doctor Recommended OTC Topical Anti-Itch Brand*, is teaming up with the National Park Foundation and outdoor advocate Dylan Efron this summer to help more people enjoy nature—without the itch

PitchBook
Jun 5th, 2025
Opella's €8B Buyout Boosts PE Deals

PE investment in Europe's healthcare sector reached €15.4 billion in Q1, driven by large-cap buyouts. Two-thirds of this value came from two major deals: Clayton, Dubilier & Rice's €8 billion buyout of Opella and KKR's €2.6 billion acquisition of Karo Healthcare. This marks a 40% increase from the previous year. Despite the high deal value, deal volume dropped to 119 from 162 and 155 in Q3 and Q4 2024, respectively, as PE investment focuses on fewer, larger deals.